Effectiveness and Safety of Avatrombopag in Liver Cancer Patients with Severe Thrombocytopenia: Real-World Data and Challenges

Figure 3

Thrombopoietic effect of combined avatrombopag with other thrombopoietic drugs and repeated use in liver cancer patients. (a) Thrombopoietic effect of avatrombopag in patients with and without combination treatment; (b) percentages of responders in patients with and without combination treatment; (c) thrombopoietic effect of patients with initial and second use of avatrombopag; (d) percentages of responder in patients with initial and second use of avatrombopag.

(a)

(b)

(c)

(d)